AHUS - ATYPICAL HEMOLYTIC UREMIC SYNDROME

Clinical trials for AHUS - ATYPICAL HEMOLYTIC UREMIC SYNDROME explained in plain language.

Never miss a new study

Get alerted when new AHUS - ATYPICAL HEMOLYTIC UREMIC SYNDROME trials appear

Sign up with your email to follow new studies for AHUS - ATYPICAL HEMOLYTIC UREMIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for rare aHUS: experimental drug targets blood clots and kidney failure

Disease control Not yet recruiting

This study tests a new drug called NM8074 in 12 adults with a rare disease called atypical hemolytic uremic syndrome (aHUS), which causes blood clots, low platelets, and kidney damage. The goal is to see if the drug can stop these symptoms and improve kidney function. Participant…

Matched conditions: AHUS - ATYPICAL HEMOLYTIC UREMIC SYNDROME

Phase: PHASE2 • Sponsor: NovelMed Therapeutics • Aim: Disease control

Last updated Apr 29, 2026 06:59 UTC

AHUS - ATYPICAL HEMOLYTIC UREMIC SYNDROME

Get alerted when new AHUS - ATYPICAL HEMOLYTIC UREMIC SYNDROME trials appear

New hope for rare aHUS: experimental drug targets blood clots and kidney failure